CHMP recommends approval of 12 drugs at September meeting

The European Medicines Agency’s expert committee has recommended seven new drugs, one biosimilar treatment, and four generic options, bringing the year’s total of approved medications up to 70.


At its meeting in September, the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has given a positive opinion on 12 medications.

First on the list is Sanofi and Astrazeneca’s Beyfortus (nirsevimab), a preventive treatment for respiratory syncytial virus (RSV), a lower respiratory tract disease, in newborns and infants. This is the world’s first and so far only preventive drug for RSV, a disease area where an intense development race is currently taking place that includes players like Pfizer, Moderna, GSK, and Bavarian Nordic.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs